Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Andol S is a combination pharmaceutical product developed and manufactured by the Vietnamese company Imexpharm (IMP MMC). It is formulated for the symptomatic relief of the common cold, influenza, and allergic rhinitis. The medication contains two primary active ingredients: paracetamol (acetaminophen) and chlorphenamine maleate. Paracetamol acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system, effectively reducing fever and pain. Chlorphenamine maleate is a first-generation alkylamine antihistamine that functions as a competitive antagonist at H1 histamine receptors, thereby alleviating symptoms such as rhinorrhea (runny nose), sneezing, and watery eyes. Andol S is approved and widely marketed in Vietnam as an over-the-counter treatment for flu-like symptoms, headache, and nasal congestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + chlorphenamine (Imexpharm).